Oral GLP-1 medicines: how daily tablets differ from injections

Oral semaglutide is a tablet formulation of a GLP-1 receptor agonist. It was developed with an absorption enhancer so that a peptide medication, which would otherwise be poorly absorbed through the digestive tract, can reach the bloodstream after being swallowed.

Different semaglutide products have different approved indications and dosing schedules. A prescription should therefore be based on the exact product, the patient's medical history and the treatment goal rather than on the ingredient name alone.

GLP-1 receptor agonists mimic part of the signalling of the naturally occurring GLP-1 hormone. Their effects are relevant to both glucose regulation and appetite.

One consequence of that appetite effect is worth naming honestly, because patients are rarely warned about it. Many people describe not just reduced hunger but a reduced interest in food generally, and for some that is a relief while for others it is unexpectedly flattening. Meals stop being enjoyable, and eating becomes a task. That is a normal effect of the drug rather than a personal failing, and it is worth raising at follow-up rather than enduring silently.

Oral semaglutide has specific administration instructions because food, beverages and other medicines can affect absorption. Patients should follow the instructions for their prescribed product exactly — this is not a tablet that can be taken casually with breakfast, and taking it incorrectly can substantially reduce how much medicine is absorbed.

Managing the gastrointestinal effects

Most nausea occurs during dose escalation and settles as the body adjusts. Smaller portions, eating more slowly, stopping when full rather than when the plate is empty, and reducing fatty or very rich meals all help. Severe or persistent vomiting is a different matter and warrants review rather than perseverance, because dehydration is a real risk.

Neither format is inherently superior. The daily tablet avoids needles but demands consistency; the weekly injection is a single action but requires comfort with self-injection. The better choice is usually the one a particular person will actually take correctly over months, which is a practical question rather than a pharmacological one.

GLP-1 receptor agonists are prescription treatments with genuine contraindications. A proper assessment exists to identify them, which is one reason these medicines should not be obtained without one.

• A personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia type 2.
• Previous pancreatitis, which requires careful discussion before any GLP-1 is considered.
• Pregnancy, planned pregnancy or breastfeeding — these medicines are stopped in advance of conception.
• Significant gastrointestinal disease such as gastroparesis.
• Active or previous eating disorder, where appetite-suppressing medication can be actively harmful.
• A body weight already in the healthy range, where the risk-benefit balance does not support treatment.

That fifth point deserves emphasis. These medicines are increasingly sought by people whose weight is not a medical problem, and appetite suppression in someone with disordered eating can entrench the disorder rather than help. Treatment aimed at health is a different proposition from treatment aimed at appearance, and a responsible prescriber will make that distinction.

Weight lost on GLP-1 therapy is not purely fat. A proportion of it is lean tissue, as is true of most substantial weight loss, and preserving muscle matters for strength, metabolic rate and long-term function. Adequate protein intake and resistance exercise are not optional extras alongside these medicines — they are what determines the quality of the weight lost.

What happens if you stop

Weight regain after stopping is common and well documented. This is a physiological consequence of removing a treatment that was suppressing appetite, not a failure of willpower, and the framing matters because people who regain weight often conclude they have failed and avoid seeking help again.

The practical implication is that these medicines are best understood as treatment for an ongoing condition rather than a course with an endpoint. Anyone starting should have thought about what happens after — whether that means continuing, tapering with a structured plan, or accepting some regain — before rather than after.

Demand has produced a substantial grey market in GLP-1 products bought online, through social media or from overseas sellers. Products obtained this way may be counterfeit, incorrectly dosed, contaminated or entirely different substances, and dosing errors with concentrated preparations have caused serious harm internationally. There is no way to verify what is in an unregulated vial, and no prescriber overseeing the dose escalation.

If cost is what is driving someone toward those channels, that is worth saying openly at a consultation. It is a legitimate constraint and there may be alternatives; it is a considerably better conversation than an unsupervised purchase.

GLP-1 medicines are prescription treatments and are not suitable for everyone. Before treatment, a clinician should review relevant medical history, current medicines, weight-related conditions and the likelihood of side effects. Follow-up is important for dose adjustment, nutrition and preservation of lean mass during weight loss.

Assessment also identifies whether something else is contributing. Untreated sleep apnoea, thyroid disease, certain medications and other conditions all affect weight, and finding one of those changes the plan meaningfully. Weight is a symptom as often as it is a diagnosis.

For the injectable format specifically, see our guide to weekly weight-loss injections. Where weight sits alongside blood pressure, glucose or cholesterol concerns, our chronic disease management service covers longer-term monitoring, and health screening can identify contributing conditions before treatment begins.